hydroxyurea has been researched along with Kidney Failure, Chronic in 12 studies
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We are unsure if hydroxyurea improves glomerular filtration rate or reduces hyperfiltration in children aged nine to 18 months, but it may improve their ability to concentrate urine and may make little or no difference to the incidence of acute chest syndrome, painful crises, and hospitalisations." | 5.41 | Interventions for chronic kidney disease in people with sickle cell disease. ( Carpenter, A; Dale-Harris, I; Dorée, C; Estcourt, LJ; Roy, NB, 2023) |
| "Treatment with hydroxyurea for 24 months did not influence GFR in young children with SCA." | 2.77 | Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. ( Alvarez, O; Howard, T; Iyer, RV; Luo, Z; McCarville, MB; Miller, ST; Rana, SR; Rogers, ZR; Sarnaik, SA; Schwartz, GJ; Thompson, B; Thornburg, CD; Wang, WC; Ware, RE, 2012) |
| " On the basis of the exposure and the apparent clearance from the current and 2 historical studies, the authors have proposed an initial dosing regimen of hydroxyurea (7." | 2.71 | The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. ( Ataga, K; Gothelf, S; Grasela, DM; Kaul, S; Kutlar, A; Olson, JS; Orringer, E; Yan, JH, 2005) |
| "Zileuton was well tolerated by all participants including those with severe renal impairment and those receiving hemodialysis." | 2.68 | Pharmacokinetics of zileuton and its metabolites in patients with renal impairment. ( Awni, WM; Chu, SY; Drajesk, J; Halstenson, CE; Hansen, R; Keane, WF; Machinist, JM; Patterson, K; Wong, S, 1997) |
| " All other treatments were continued with some dosage adjustments." | 1.35 | Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis. ( Demulder, AC; Malarme, M; Mesquita, Mdo C; Noubouossie, D; Sol, EB, 2009) |
| "Enalapril treatment for 3." | 1.33 | Enalapril and hydroxyurea therapy for children with sickle nephropathy. ( Fitzhugh, CD; Ware, RE; Wigfall, DR, 2005) |
| "Thymidine incorporation was greatest at 0." | 1.25 | Effect of calcium and magnesium on deoxyribonucleic acid synthesis in rat parathyroid glands in vitro. ( Lee, MJ; Roth, SI, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Roy, NB | 2 |
| Carpenter, A | 1 |
| Dale-Harris, I | 1 |
| Dorée, C | 2 |
| Estcourt, LJ | 2 |
| Fortin, PM | 1 |
| Bull, KR | 1 |
| Trivella, M | 1 |
| Hopewell, S | 1 |
| Hariri, E | 1 |
| Mansour, A | 1 |
| El Alam, A | 1 |
| Daaboul, Y | 1 |
| Korjian, S | 1 |
| Aoun Bahous, S | 1 |
| Mesquita, Mdo C | 1 |
| Sol, EB | 1 |
| Malarme, M | 1 |
| Noubouossie, D | 1 |
| Demulder, AC | 1 |
| Alvarez, O | 1 |
| Miller, ST | 1 |
| Wang, WC | 1 |
| Luo, Z | 1 |
| McCarville, MB | 1 |
| Schwartz, GJ | 1 |
| Thompson, B | 1 |
| Howard, T | 1 |
| Iyer, RV | 1 |
| Rana, SR | 1 |
| Rogers, ZR | 1 |
| Sarnaik, SA | 1 |
| Thornburg, CD | 1 |
| Ware, RE | 2 |
| Ohashi, N | 1 |
| Yonemura, K | 1 |
| Sugiura, T | 1 |
| Isozaki, T | 1 |
| Togawa, A | 1 |
| Fujigaki, Y | 1 |
| Yamamoto, T | 1 |
| Hishida, A | 1 |
| La Spina, M | 1 |
| Russo, G | 1 |
| Fitzhugh, CD | 1 |
| Wigfall, DR | 1 |
| Yan, JH | 1 |
| Ataga, K | 1 |
| Kaul, S | 1 |
| Olson, JS | 1 |
| Grasela, DM | 1 |
| Gothelf, S | 1 |
| Kutlar, A | 1 |
| Orringer, E | 1 |
| Losada, R | 1 |
| Bravo, I | 1 |
| Capildeo, K | 1 |
| Charles, K | 1 |
| Awni, WM | 1 |
| Wong, S | 1 |
| Chu, SY | 1 |
| Patterson, K | 1 |
| Hansen, R | 1 |
| Machinist, JM | 1 |
| Drajesk, J | 1 |
| Keane, WF | 1 |
| Halstenson, CE | 1 |
| Lee, MJ | 1 |
| Roth, SI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)[NCT00006400] | Phase 3 | 193 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DTPA GFR was originally a co-primary efficacy outcome for the study. Later in May 29, 2009, this measurement was discontinued because of statistical futility (an extremely small chance that the difference between treatment groups would be statistically significant for this outcome) and the small risk posed by the radiation exposure involved with performing the DTPA GFR test. Subjects who had missing data at baseline or 2 years measurement were excluded from the analysis (29 subjects from the hydroxurea, and 31 subjects from the placebo group excluded). (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 22.56 |
| Placebo | 20.74 |
GFR was calculated using new Schwartz formula: 39.1× [height (cm)/serum creatinine (mg/dL)]0.516 × [1.8/cystatin C]0.294 × [30/blood urea nitrogen]0.169 × [1.099]if male × [height(m)/1.4]0.188. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 10.57 |
| Placebo | 14.33 |
Schwartz formula used to calculate GFR is: 0.55× height (cm)/serum creatinine (mg/dL). Where height is in cm and serum creatinine is in mg/dL. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 28.65 |
| Placebo | 33.36 |
4 reviews available for hydroxyurea and Kidney Failure, Chronic
| Article | Year |
|---|---|
Interventions for chronic kidney disease in people with sickle cell disease.
Topics: Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Angiotensin-Converting Enzyme Inhibito | 2023 |
Interventions for chronic kidney disease in people with sickle cell disease.
Topics: Adult; Albuminuria; Anemia, Sickle Cell; Angiotensin-Converting Enzyme Inhibitors; Antisickling Agen | 2017 |
Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment.
Topics: Analgesics; Anemia, Sickle Cell; Biomarkers; Glomerular Filtration Rate; Hematuria; Humans; Hydroxyu | 2018 |
New drugs for childhood anemia.
Topics: Adult; Age Factors; Anemia; Anemia, Hemolytic, Autoimmune; Anemia, Sickle Cell; Antibodies, Monoclon | 2003 |
3 trials available for hydroxyurea and Kidney Failure, Chronic
| Article | Year |
|---|---|
Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Creatinine; Cystatin C; Double-Blind Method; Female; Glome | 2012 |
The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease.
Topics: Adult; Aged; Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Kidney; Kidney Failure, Chronic; Kidn | 2005 |
Pharmacokinetics of zileuton and its metabolites in patients with renal impairment.
Topics: Adult; Aged; Female; Humans; Hydroxyurea; Kidney Diseases; Kidney Failure, Chronic; Kidney Function | 1997 |
5 other studies available for hydroxyurea and Kidney Failure, Chronic
| Article | Year |
|---|---|
Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
Topics: Aged; Aspirin; Blood Cell Count; Blood Chemical Analysis; Blood Transfusion; Drug Resistance; Erythr | 2009 |
Withdrawal of interferon-alpha results in prompt resolution of thrombocytopenia and hemolysis but not renal failure in hemolytic uremic syndrome caused by interferon-alpha.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Hemolysis; Hemolytic-Uremic Syndrome; Humans; | 2003 |
Enalapril and hydroxyurea therapy for children with sickle nephropathy.
Topics: Adolescent; Albuminuria; Anemia, Sickle Cell; Antihypertensive Agents; Antisickling Agents; Child; C | 2005 |
Is the group of older sickle cell disease patients from Trinidad and Tobago different?
Topics: Adult; Aged; Aging; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Female; Foot Ulcer; | 2006 |
Effect of calcium and magnesium on deoxyribonucleic acid synthesis in rat parathyroid glands in vitro.
Topics: Animals; Autoradiography; Calcium; Deoxycytidine; DNA; Humans; Hydroxyurea; Hyperplasia; Kidney; Kid | 1975 |